FSD Pharma, Inc.
π¨π¦Canada
- Country
- π¨π¦Canada
- Ownership
- Public
- Established
- 1994-10-20
- Employees
- 11
- Market Cap
- -
- Website
- http://www.fsdpharma.com
Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: Lucid-21-302Drug: Placebo
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- FSD Pharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05821387
- Locations
- π¨π¦
Biopharma Services Incorporated, Toronto, Ontario, Canada
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
Phase 2
Terminated
- Conditions
- Mast Cell Activation Disorder IdiopathicMast Cell Activation Syndrome
- Interventions
- Drug: FSD201Drug: Placebo
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- FSD Pharma, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05652907
- Locations
- πΊπΈ
Saint Charles Clinical Research, Weldon Spring, Missouri, United States
π¨π¦Toronto Rehabilitation Institute, Toronto, Ontario, Canada
πΊπΈNorman Marcus Pain Institute, New York, New York, United States
Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
Phase 2
Terminated
- Conditions
- COVID-19
- Interventions
- Drug: FSD201Drug: PlaceboOther: Standard of Care for Covid-19
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- FSD Pharma, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT04619706
- Locations
- πΊπΈ
Kingsport, Tennessee, Kingsport, Tennessee, United States
πΊπΈButte, Montana, Butte, Montana, United States
πΊπΈAmarillo, Texas, Amarillo, Texas, United States
Β© Copyright 2025. All Rights Reserved by MedPath